Alzheimer Disease

Donanemab was able to significantly slow clinical progression of Alzheimer disease and amyloid and tau pathology at 76 weeks of treatment.

Data have shown the potential for the therapy to treat several new conditions.

Results from the INCREASE study shed light on the value of the pharmacist in medication therapy management.

If approved, the test could provide more timely and accurate diagnosis, hopefully mitigating the impact of Alzheimer disease (AD) on individuals and the community.

Linking strong anticholinergic medications to increased risk of dementia in older adults

A study about modifiable risk factors on a “weak spot” in the brain network found that diabetes, pollution, and alcohol were most likely to contribute to dementia disorders.

Investigators found that mRNA technology for the delivery of antibody therapeutics were used to target tau in Alzheimer disease and can be applied to other tau targets.

The FDA is convening a committee to discuss phase 3 data after the planned action date, which delays drug availability to patients.

The device conducts blood biomarker tests that accurately diagnose amyloid pathology and can assist in diagnosing Alzheimer disease in patients with cognitive impairment.

The authors emphasize that further research on a diverse population that focuses on the role of duration and lifestyle choices and neuroinflammatory markers should be performed.

The company will discontinue the development and commercialization of aducanumab-avwa (Aduhelm) for intravenous use and will terminate the ENVISION clinical study.

BrainSee creates a new standard for progression prediction in Alzheimer disease, marking a step forward in brain health management with non-invasive screening.

Those who were exposed to the clinically acquired stomach bacteria had a 24% increased risk of Alzheimer disease after a decade of onset.

Although machine learning models demonstrate potential to improve early detection of Alzheimer disease, sample sizes that underrepresent ethnic and racial groups result in unfairness.

The pattern for the diminished learning curve, associated with elevated amyloid levels, was consistent across 3 memory tasks, with strongest results for recalling digit-signs and groceries prices.

Patients who receive stimulation at different parts of the brain may reap benefits.

From newsworthy moments to groundbreaking research, these were the most-read Alzheimer disease-related articles on Pharmacy Times in 2023.

With gastrointestinal-based adverse effectss for rivastigmine and other cholinesterase inhibitors, a weight of <50 and <55 kg respectively leads to an increased risk for toxicities.

Investigators analyzed the effects of harmful accumulation of HDAC6 in the brains of mouse models with Alzheimer disease to determine any changes in disease progression.

Investigators found that individuals who self-identified as Black were less frequently imaged for cognitive impairment with MRI and at an older age compared with White and Hispanic patients.

Investigators believe lowering cholesteryl ester levels could help prevent brain damage and behavioral changes, reducing the risk of Alzheimer disease.

Food insecurity was associated with an increased risk of dementia, poorer memory function, and faster memory decline in older adults.

The drug may be a risk factor for dementia-related illnesses.

In May 2023, the FDA approved brexpiprazole as the first and only drug to receive approval for treatment of agitation associated with Alzheimer Disease dementia.

Study also showed that 76% of individuals treated with lecanemab-irmb had no deterioration in the tau positron emission tomography (PET) subset.

A weekly dose of injectable lecanemab-irmb (Leqembi) could allow patients with Alzheimer disease to receive the drug at home instead of visiting an infusion center twice per month.

Approximately 96% physicians feel it is important to assess patients aged 60 years and older for cognitive impairment, but 48% of these patients have no had assessments from their physician.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody that targets amyloid plaques, which are thought to play a role in the development and progression of Alzheimer disease.

Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.